FY25 Results: Resilient Performance with Strong Profit Gains in Challenging Markets

About this update from Medmix Ag

[{"type":"text","content":"Baar, Switzerland--(Newsfile Corp. - February 26, 2026) - Ad hoc announcement pursuant to Art. 53 LR","length":100,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"val":[{"type":"text","content":"MEDIA RELEASE","length":13,"tagName":"p"},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"Full-Year 2025 Results","length":22,"tagName":"p"}]},{"val":[]},{"val":[{"type":"text","content":"","length":0,"tagName":"p"}]}]}],"length":81},{"type":"text","content":"Download Press Release","length":22,"tagName":"p"},{"type":"text","content":"Download Photo Sven Luginbuehl","length":30,"tagName":"p"},{"type":"text","content":"Resilient Performance with Strong Profit Gains in Challenging Markets","length":69,"tagName":"p"},{"type":"text","content":"FULL-YEAR 2025 HIGHLIGHTS","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue at CHF 448m, -4.8% FX org. adj. (-7.4% nominal); growth in Dental, Surgery and Industry offset by softer demand in Beauty and impact of customer dual sourcing in Drug Delivery","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"Adj. EBITDA margin at 20.0% (+90bps YoY), on higher Dental volume, significantly higher gross margin and lower OPEX","length":115,"tagName":"p"}]},{"val":[{"type":"text","content":"Net income at CHF 7.0m from CHF -6.4m in 2024","length":45,"tagName":"p"}]},{"val":[{"type":"text","content":"Lower Operating Net Cash Flow (ONCF) at CHF 40.3m after elevated 2024","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"On track with Growth and Efficiency program: 2024/2025 CHF 22.6m savings impact and already CHF 4.3m secured for 2026","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"Sven Luginbühl appointed as new CFO; Jennifer Dean to lead Beauty business unit","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Dividend of CHF 0.10 per share proposed","length":39,"tagName":"p"}]},{"val":[{"type":"text","content":"2026 guidance: flat to low single digit organic revenue growth, adjusted EBITDA margin of around 20%","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Confirmed mid-term revenue CAGR of above 4%, increased adj. EBITDA margin of above 21%","length":86,"tagName":"p"}]}],"tagName":"ul","bulletedList":true...

More updates from Medmix Ag